Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HF-REVERT phase 2 study of CDR132L after myocardial infarction with reduced LVEF
NL-OMON60738Phase 2Completed
- Sponsor
- Cardior Pharmaceuticals
- Start
- Jun 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of CDR132L in myocardial infarction (MI) and heart failure (HF) (3 arms), sponsored by Cardior Pharmaceuticals. Primary endpoint: Percent change from baseline in LVESVI at Month 6. Started Jun 2022; status: completed.
02
Drugs
CDR132L
03
Conditions
myocardial infarction (MI)heart failure (HF)
Beyond the preview
Go deeper on NL-OMON60738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60738.